Cover Image

HARDBACK
$52.95



View/Hide Left Panel

References

Abraham R, Minor P, Dunn G, et al. Shedding of virulent poliovirus revertants during immunization with oral polio vaccine after prior immunization with inactivated polio vaccine. Journal of Infectious Diseases 1993; 168:1105–1109.

ACP (American College of Physicians). Guide for Adult Immunization, 2nd ed. Philadelphia: American College of Physicians, 1990.

Allan CH, Mendrick DL, Trier JS. Rat intestinal M cells contain acidic endosomallysosomal compartments and express class 11 major histocompatibility complex determinants. Gastroenterology 1993; 104:698–708.


Baker CJ, Rench MA, Edwards MS, et al. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. New England Journal of Medicine 1988; 319:917–921.

Bart K, Foulds J, Patricia P. The global eradication of poliomyelitis: benefit-cost analysis. Bulletin of the World Health Organization 1996; 74:1.

Bennett NM, Lewis B, Doninger AS et al. A coordinated, community-wide program in Monroe County, New York, to increase influenza immunization rates in the elderly. Archives of Internal Medicine 1994; 154:1741–1745.

Bergner M, Bobbit RA, Carter WB, et al. The sickness impact profile: development and final revision of a health status measure. Medical Care 1981; 19:787–805.

Berthelot JM, Roberge R, Wolfson MC. The calculation of health-adjusted life expectancy for a Canadian province using a multi-attribute utility function: a first attempt. In 6th Working-Group Meeting REVES, International Research Network for Interpretation of Observed Values of Health Life Expectancy, Montpelier, Vermont, October 1992.

Bodian D. Differentiation of types of poliomyelitis viruses. 1. Reinfection experiments in monkeys (second attacks). American Journal of Hygiene 1949; 49: 200–224.

Bodian D. Poliomyelitis immunization. Mass use of oral vaccine in the United States might prevent definitive evaluation of either vaccine. Science 1961; 134:819.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 133
Vaccines for the 21st Century: A Tool for Decisionmaking References Abraham R, Minor P, Dunn G, et al. Shedding of virulent poliovirus revertants during immunization with oral polio vaccine after prior immunization with inactivated polio vaccine. Journal of Infectious Diseases 1993; 168:1105–1109. ACP (American College of Physicians). Guide for Adult Immunization, 2nd ed. Philadelphia: American College of Physicians, 1990. Allan CH, Mendrick DL, Trier JS. Rat intestinal M cells contain acidic endosomallysosomal compartments and express class 11 major histocompatibility complex determinants. Gastroenterology 1993; 104:698–708. Baker CJ, Rench MA, Edwards MS, et al. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. New England Journal of Medicine 1988; 319:917–921. Bart K, Foulds J, Patricia P. The global eradication of poliomyelitis: benefit-cost analysis. Bulletin of the World Health Organization 1996; 74:1. Bennett NM, Lewis B, Doninger AS et al. A coordinated, community-wide program in Monroe County, New York, to increase influenza immunization rates in the elderly. Archives of Internal Medicine 1994; 154:1741–1745. Bergner M, Bobbit RA, Carter WB, et al. The sickness impact profile: development and final revision of a health status measure. Medical Care 1981; 19:787–805. Berthelot JM, Roberge R, Wolfson MC. The calculation of health-adjusted life expectancy for a Canadian province using a multi-attribute utility function: a first attempt. In 6th Working-Group Meeting REVES, International Research Network for Interpretation of Observed Values of Health Life Expectancy, Montpelier, Vermont, October 1992. Bodian D. Differentiation of types of poliomyelitis viruses. 1. Reinfection experiments in monkeys (second attacks). American Journal of Hygiene 1949; 49: 200–224. Bodian D. Poliomyelitis immunization. Mass use of oral vaccine in the United States might prevent definitive evaluation of either vaccine. Science 1961; 134:819.

OCR for page 133
Vaccines for the 21st Century: A Tool for Decisionmaking Boyle MH, Furlong W, Feeny GW, et al. Reliability of the Health Utilities Index—Mark III used in the 1991 cycle 6 Canadian General Social Survey Health Questionnaire. Quality of Life Research 1995; 4:249–257. Brodie M, Park WH. Active immunization against poliomyelitis. American Journal of Public Health 1936; 26:119–125. Buffington J, Bell KM, LaForce FM. The Genesee Hospital Medical Staff. A target-based model for increasing influenza immunizations in private practice. Journal of General Internal Medicine 1991; 6:204–209. Catlin G, Will P. The national population health survey: highlights of initial developments. Health Reports 1992; 4(3):313–319. CDC (Centers for Disease Control and Prevention). Certification of poliomyelitis eradication in the Americas. Morbidity and Mortality Weekly Report 1994a; 54:720–722. CDC. General recommendations on immunization. Recommendations of the advisory committee on immunization practices (ACIP). Morbidity and Mortality Weekly Report 1994b; 43(No. RR-1-4). CDC. Summary of notifiable diseases, United States, 1994. Morbidity and Mortality Weekly Report 1994c; 43(53). CDC. Influenza and pneumococcal vaccination coverage levels among persons aged greater than or equal to 65 years 1973–1993—United States 1995. Morbidity and Mortality Weekly Report 1995a; 44:506–507, 513–515. CDC. Mass vaccination with oral poliovirus vaccine—Asia and Europe. Morbidity and Mortality Weekly Report 1995b; 44:234–236. CDC. Progress towards global poliomyelitis eradication 1985–1994. Morbidity and Mortality Weekly Report 1995c; 44:273–275, 281. CDC. Recommended childhood immunization schedule. Morbidity and Mortality Weekly Report 1995d:44:1–9. CDC. National, state, and urban area vaccination coverage levels among children aged 19–35 months—United States, July 1996–June 1997. Morbidity and Mortality Weekly Report 1998; 47:108–116. CDC. Recommended childhood immunization schedule—United States, 1999. Morbidity and Mortality Weekly Report 1999; 48:12–16. Chatfield SN, Fairweather N, Charles I, et al. Construction of a genetically defined Salmonella typhi Ty2 aroa, aroc mutant for the engineering of candidate oral typhoid-tetanus vaccine. Vaccine 1992; 10:53–60. Chen ST, Edsall G, Pell MM, et al. Timing of antenatal tetanus immunization for effective protection of the neonate. Bulletin of the World Health Organization 1983; 61:159–165. Claassen I, Osterhaus A. The ISCOM structure as an immune-enhancing moiety: experience with viral systems. Research Immunology 1992; 143:531–541. Coffman RL, Varkila K, Scott P, et al. Role of cytokines in the differentiation of CD4+ T-cell subsets in vivo. Immunology Review 1991; 123:189–207. Commission on the Cost of Medical Care. The Economic Significance of the Prevention of Paralytic Poliomyelitis 1955–1961. Report of the Commission on the Cost of Medical Care 1964; 4:29–46. Comroe JH, Dripps RD. Scientific basis for the support of biomedical science. Science 1976; 192:105–111.

OCR for page 133
Vaccines for the 21st Century: A Tool for Decisionmaking Conley ME, Delacroix DL. Intravascular and mucosal immunoglobulin A: two separate but related systems of immune defense. Annals of Internal Medicine 1987; 106:892–899. Czinn SJ, Cai A, Nedrud JG. Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization. Vaccine 1993; 11:637–642. Davies MDJ, Parrott DMW. Cytotoxic T cells in small intestine epithelial, lamina propria and lung lymphocytes. Immunology 1981; 44:367–371. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes , New York: Oxford University Press, 1987. Eddy, DM. Oregon’s methods: did cost-effectiveness analysis fail? Journal of the American Medical Association 1991; 266:2135–2141. Eldridge JH, Hammond CJ, Meulbroek JA, et al. Controlled vaccine release in the gut-associated lymphoid tissue. Orally administered biodegradable microspheres target the Peyer’s patches. Controlled Release 1990; 11:205–214. Enders JF. General preface to studies on the cultivation of poliomyelitis viruses in tissue culture. Journal of Immunology 1952; 69:639. Enders JF, Weller TH, Robinson FC. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 1949; 109: 85–87. Erickson P, Wilson R, Shannon I. Years of Healthy Life. Healthy People 2000 Statistical Notes. No. 7:95–1237. Hyattsville, Md.: National Center for Health Statistics, 1995. Ermak TH, Dougherty EP, Bhagat HR, et al. Uptake and transport of copolymer biodegradable microspheres by rabbit Peyer’s patch M cells. Cell and Tissue Research 1995; 279:433–436. Ernst PB, Befus AD, Bienenstock J. Leukocytes in the intestinal epithelium: an unusual immunological compartment. Immunology Today 1985; 6:50–55. Farstad IN, Halstensen TS, Fausa O, et al. Heterogeneity of M-cell-associated B and T cells in human Peyer’s patches. Immunology 1994; 83:457–464. Fedson DS. Influenza and pneumococcal immunization strategies for physicians. Chest 1981; 91:436–443. Fedson DS. Influenza and pneumococcal vaccination in Canada and the United States, 1980–1993: what can the two countries learn from each other? Clinical Infectious Diseases 1995; 20:1371–1376. Feeny D, Furlong W, Boyle M, et al. Multi-attribute health status classification systems: health utilities index. PharmacoEconomics 1995; 7:490–502. Fynan EF, Webster RG, Fuller DH, et al. DNA vaccines: protective immunization by parenteral, mucosal and gene-gun inoculations. Proceedings of the National Academy of Sciences 1993; 90:11478–11482. General Accounting Office. Immunization: Health and Human Services Could Do More to Increase Vaccination Among Older Adults. A report to congressional requesters. GAO/PEMD-95–14. Washington, D.C.: General Accounting Office; 1995. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness In Health and Medicine. New York: Oxford University Press, 1996.

OCR for page 133
Vaccines for the 21st Century: A Tool for Decisionmaking Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunology Today 1990; 11:89–97. Guyer B, Hughart N, Holt E, et al. Immunization coverage and its relationship to preventive health care visits among inner-city children in Baltimore. Pediatrics 1994; 94:53–58. Halsey N, Klein D. Report of a workshop: immunization of pregnant women. Pediatric Infectious Disease Journal 1990; 9:574–581. Haq TA, Mason HS, Clements JD, et al. Oral immunization with a recombinant bacteria antigen produced in transgenic plants. Science 1995; 268:714–716. Harrington H. Review of literature in International Committee for the Study of Infantile Paralysis. Poliomyelitis: A survey made possible by a grant from the International Committee for the Study of Infantile Paralysis. Baltimore, Md.: Williams & Wilkins Co.; 1932:130–144. HCFA (Health Care Financing Administration). Health Care Financing Review: Medicare and Medicaid Statistical Supplement. HCFA Pub. No. 03348. Baltimore, Md.: U.S. Department of Health and Human Services, 1995. Health Information Foundation. The changing status of polio. Progress in Health Services. 1959; 8:1–6. Hinman AR, Koplan JP, Orenstein WA, et al. Live or inactivated poliomyelitis vaccine: an analysis of benefits and risks. American Journal of Public Health 1987; 77:1–5. Hone DM, Harris AM, Chatfield S, et al. Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine 1991; 9:810–816. Hsieh CS, Macatonia SE, Tripp CS, et al. Development of Th1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260:547–549. Insel RA, Amstey M, Woodin K, et al. Immunization of pregnant women to prevent infectious diseases in the neonate or infant. International Journal of Technical Assessment of Health Care 1994; 10:143–153. IOM (Institute of Medicine). New Vaccines Development: Establishing Priorities, Vol. 1. Diseases of Importance in the United States. Washington, D.C.: National Academy Press, 1985a. IOM. New Vaccines Development: Establishing Priorities, Vol. 2. Diseases of Importance in Developing Countries. Washington, D.C.: National Academy Press, 1985b. IOM. Adverse Effects of Pertussis and Rubella Vaccines. Washington, D.C.: National Academy Press, 1991. IOM. Setting Priorities for Health Technology Assessment: A Model Process. Washington, D.C.: National Academy Press, 1992. IOM. Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality. Washington, D.C.: National Academy Press, 1994a. IOM. DPT Vaccine and Chronic Nervous System Dysfunction: A New Analysis. Washington, D.C.: National Academy Press; 1994b. IOM. The Children’s Vaccine Initiative: Continuing Activities. A Summary of Two Workshops. Washington, D.C.: National Academy Press, 1995. IOM. Options for Poliomyelitis Vaccination in the United States: Workshop Summary. Howe CJ, Johnston RB (eds.). Washington, D.C.: National Academy Press, 1996a.

OCR for page 133
Vaccines for the 21st Century: A Tool for Decisionmaking IOM. Vaccines Against Malaria: Hope in a Gathering Storm. Washington, D.C.: National Academy Press, 1996b. IOM. America’s Vital Interest in Global Health: Protecting Our People, Enhancing Our Economy, and Advancing Our International Interests. Washington, D.C.: National Academy Press, 1997a. IOM. Risk Communication and Vaccination: Summary of a Workshop. Washington, D.C.: National Academy Press, 1997b. IOM. Summarizing Population Health: Directions for the Development and Application of Population Metrics. Washington, D.C.: National Academy Press, 1998. Jones BD, Ghori N, Falkow S. Salmonella typhimurium initiates murine infection by penetrating and destroying the specialized epithelial M cells of the Peyer’s patches. Experimental Medicine 1994; 180:15–23. Kaetzel CS, Robinson JK, Chintalacharuvu KR, et al. The polymeric immunoglobulin receptor (secretory component) mediates transport of immune complexes across epithelial cells: a local defense function for IgA. Proceedings of the National Academy of Sciences 1991; 88:8796–8800. Kaetzel CS, Robinson JK, Lamm ME. Epithelial transcytosis of monomeric IgA and IgG cross-linked through antigen to polymeric IgA. A role for monomeric antibodies in the mucosal immune system. Immunology 1994; 152:72–76. Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Services Research 1988; 23:203–235. Kind P, Gudex CM. Measuring health status in the community: a comparison of methods. Journal of Epidemiology and Community Health 1994; 486:86–91. Kolmer JA, Klugh Jr. G, Rule AM. A successful method for vaccination against acute anterior poliomyelitis. Journal of the American Medical Association 1935; 104:456–460. Koprowski H, Jervis GA, Norton TW. Immune responses in human volunteers upon oral administration of a rodent-adapted strain of poliomyelitis virus. American Journal of Hygiene 1952; 55:108–126. Kraehenbuhl JP, Neutra MR. Molecular and cellular basis of immune protection of mucosal surfaces. Physiological Reviews 1992; 72:853–879. Landauer KS, Stickle G. An analysis of residual disabilities (paralysis and crippling) among 100,000 poliomyelitis patients with special reference to the rehabilitation of past poliomyelitis patients. Archives of Physical Medical Rehabilitation 1958; 39:141–151. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for U.S. children. Journal of the American Medical Association 1994; 271:375–381. Linder N, Ohel G. In utero vaccination. Clinical Perinatology 1994; 21:663–674. Ma JCK, Hiatt A, Hein M, et al. Generation and assembly of secretory antibodies in plants. Science 1995; 268:716–719. Mazanec MB, Nedrud JG, Kaetzel CS, et al. Intracellular neutralization of virus by immunoglobulin A antibodies. Proceedings of the National Academy of Sciences 1992; 89:6901–6905. Mazanec MB, Nedrud JG, Kaetzel CS, et al. A three-tiered view of the role of IgA in mucosal defense. Immunology Today 1993; 14:430–435.

OCR for page 133
Vaccines for the 21st Century: A Tool for Decisionmaking McCormick J, Gusmao, H, Nakamura S, et al. Antibody response to serogroup A and C meningococcal polysaccharide vaccine in infants born of mothers vaccinated during pregnancy. Journal of Clinical Investigation 1980; 65:1141–1144. McDonald CJ, Hui SL, Tierney WM. Computing—effects of computer reminders for influenza vaccination on morbidity during influenza epidemics. MD Computing 1992; 9:304–312. McDowell I, Newell C. Measuring Health: A Guide to Rating Scales and Questionnaires. Second edition. New York: Oxford University Press, 1996. Mercer Management Consulting. Report on the United States Vaccine Industry. New York: Mercer Management Consulting, 1995. Merkel PA, Caputo GC. Evaluation of a simple office-based strategy for increasing influenza vaccine administration and the effect of differing reimbursement plans on the patient acceptance rate. Journal of General Internal Medicine 1994; 9:679–683. Mestecky J, McGhee JR. Immunoglobulin A (IgA): Molecular and cellular interactions involved in IgA biosynthesis and immune response. Advances in Immunology 1987; 40:153–245. Michetti P, Mahan MJ, Slauch JM, Mekalanos JJ, Neutra MR. Monoclonal secretory immunoglobulin A protects mice against oral challenge with the invasive pathogen Salmonella typhimurium. Infection and Immunity 1992; 60:1786–1792. Moldoveanu Z, Porter DC, Lu A, et al. Immune responses induced by administration of encapsidated poliovirus replicons which express HIV-1 gag and envelope proteins. Vaccine 1995; 13:1013–1022. Morein B, Sundquist B, Hoglund S, et al. ISCOM, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984; 308:457–460. Morgan IM. Immunization of monkeys with formalin-inactivated poliomyelitis viruses. American Journal of Hygiene 1948; 48:394–406. Mosmann TR, Coffman, RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annual Review of Immunology 1989; 7:145–173. Mulholland K, Suara RO, Siber G, et al. Immunization of pregnant women with Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in The Gambia. Journal of the American Medical Association 1996; 275:1182–1188. Murray, CJL, Lopez, AD, eds. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, Mass.: Harvard School of Public Health on behalf of the World Health Organization and the World Bank, 1996. NCHS (National Center for Health Statistics). 1993. Abridged Life Table, United States [WWW document]. URL: http://www.cdc.gov/nchswww/datawh/statab/unpubd/mortabs/lewk1.htm (accessed April 24, 1997). Nichol KL, Korn JE; Margolis KL, et al. Achieving the national health objective for influenza immunization: success of an institution-wide vaccine program. American Journal of Medicine 1990; 89:156–160.

OCR for page 133
Vaccines for the 21st Century: A Tool for Decisionmaking O’Dempsey TJ, McArdle T, Ceesay SJ, et al. Meningococcal antibody titres in infants of women immunized with meningococcal polysaccharide vaccine during pregnancy. Archives of Diseases of Children 1996; 74:F43–F46. O’Hagan DT, McGee JP, Holmgren J, et al. Biodegradable microparticles for oral immunization. Vaccine 1993; 11:149–154. Ogra P, Faden H. Poliovirus vaccines: Live or dead. The Journal of Pediatrics 1986; 108:1031–1033. Ogra P, Karzon D. Formation and function of poliovirus antibody in different tissues. Progress in Medical Virology 1971; 13:156–193. Owen RL, Jones AL. Epithelial cell specialization within human Peyer’s patches: an ultrastructural study of intestinal lymphoid follicles. Gastroenterology 1974; 66: 189–203. Patrick D, Erickson P. Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation. New York: Oxford University Press, 1993. Paul JR. Clinical Epidemiology. Chicago: University of Chicago Press; 1958:204– 220. Pearson DC, Thompson RS. Evaluation of Group Health Cooperative of Puget Sound’s senior influenza immunization program. Public Health Reports 1994; 109:571–578. Phillips-Quagliata JM, Lamm ME. Lymphocyte homing to mucosal effector sites. In Ogra R, Mestecky J, Lamm M, et al. (eds.), Handbook of Mucosal Immunology. Orlando, Fla.: Academic Press; 1994:225–239. Plotkin SA. Inactivated polio vaccine for the United States: a missed vaccination opportunity. Pediatric Infectious Disease Journal 1995; 14:835–839. Porter DC, Ansardi DC, Choi WS, et al. Encapsidation of genetically engineered poliovirus minireplicons which express HIV type 1 gag and pol proteins upon infection. Virology 1993; 67:3712–3719. Porter DC, Ansard DC, Morrow CD. Encapsidation of poliovirus replicons encoding the complete human immunodeficiency type virus type 1 gag gene by using a complementation system which provides the P1 capsid proteins in trans. Virology 1995; 69:1548–1555. Renegar KB, Small Jr. PA. Passive transfer of local immunity to influenza virus infection by IgA antibody. Immunology 1991; 146:1972–1978. Rivers TM, Ward SM, Baird RD. Amount and duration of immunity induced by intradermal inoculation of cultured vaccine virus. Journal of Experimental Medicine 1939; 69:857. Roberge R, Berthelot JM, Wolfson M. The health utility index: measuring health differences in Ontario by socioeconomic status. Health Reports 1995; 7:25–32. Roberts M, Chatfield SN, Dougan G. Salmonella as carriers of heterologous antigens. In: O’Hagan DT (ed.), Novel Delivery Systems for Oral Vaccines. Boca Raton, Fla.: CRC Press; 1994:27–58. Rodriguez RM, Baroff LJ. Emergency department immunization of the elderly with pneumococcal and influenza vaccines. Annals of Emergency Medicine 1993; 22: 1729–1732.

OCR for page 133
Vaccines for the 21st Century: A Tool for Decisionmaking Rosser RM. A health index and output measure. In: Walker SR, Roser RM (eds.), Quality of Life: Assessment and Application. Lancaster, England: MTP Press, 1987; 133–160. Rosser R, Cotte M, Rabin R, et al. Index of health-related quality of life. In: Hopkins A (ed.), Measure of the Quality of Life and the Uses to Which Such Measures May Be Put. London: Royal College of Physicians of London, 1992; 81–89, 147–153. Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. Journal of the American Medical Association 1996; 276: 1172–1177. Sabin AB. Characteristics and genetic potentialities of experimentally produced and naturally occurring variants of poliomyelitis virus. Annals of the New York Academy of Science 1955; 61:924–938. Sadoway DT, Loucraft JR, Johnston BA. Maximizing influenza immunization in Edmonton: a collaborative model. Canadian Journal of Public Health 1994; 85:47–50. Salk JE. Principles of immunization as applied to poliomyelitis and influenza. American Journal of Public Health 1953; 43:1384–2398. Schofield F. Selective primary health care: strategies for control of disease in the developing world. XXII. Tetanus: a preventable problem. Review of Infectious Diseases 1986; 8:144–156. Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Allergy and Clinical Immunology 1994; 94:1195–1202. Siegel B, Mahan C, Witte J, et al. Influenza and pneumococcal pneumonia immunization. Journal of Florida Medical Association 1990; 77:593–595. Smith JS. Patenting the Sun: Polio and Salk Vaccine. New York: Doubleday; 1991. St. Anthony’s Publishing, Inc. St. Anthony’s DRG Guidebook: 1996. Reston, Va.: St. Anthony’s Publishing, 1995. Sullivan DF. A single index of morbidity and mortality. HSMHA Health Reports 1971; 86(4):347–355. Tackett CO, Hone DM, Curtiss R, III, Kelly SM, Losonsky G, Guers L, Harris AM, Edelman R, Levin MM. Comparison of the safety and immunogenicity of • aroC • aroD and • cya • crp Salmonella typhi strains in adult volunteers. Infection and Immunity 1992; 60:536–541. Taylor PM, Askonas BA. Influenza nucleoprotein specific cytotoxic T cell clones are protective in vivo. Immunology 1986; 58:417–420. Thanavala Y, Yang YF, Lyons P, et al. Immunogenicity of transgenic plant-derived hepatitis B surface antigen. Proceedings of the National Academy of Sciences 1995; 92:3358–3361. The National Foundation. Poliomyelitis: Annual Statistical Review. New York: The National Foundation; 1961. The National Foundation. What You Should Know about Polio Vaccine? Publication 19. New York: The National Foundation; 1962. Torrance GW and Feeny D. Utilities and quality-adjusted life years. International Journal of Technology Assessment in Health Care 1989; 5:559–575. Torrance GW, Furlong W, Feeny D, et al. Provisional Health Status Index for the Ontario Health Survey. Final Report Submitted to Statistics Canada (Contract

OCR for page 133
Vaccines for the 21st Century: A Tool for Decisionmaking 44400900187). Hamilton, Ontario: Centre for Health Economics and Policy Analysis, McMaster University, 1992. Torrance GW, Furlong W, Feeny D, et al. Multi-attribute health preference functions: health utilities index. PharmacoEconomics 1995; 34:503–520. Waksman BH. Adjuvants and immune regulation by lymphoid cells. Springer Seminar. Immunopathology 1979; 2:5–33. Ware JE, Sherbourne DC. The MOS 36-item short-form health survey. Medical Care 1992; 30:473–483. Williams WW, Hickson MA, Kane MA, et al. Immunization policies and vaccine coverage among adults: the risk for missed opportunities. Annals of Internal Medicine 1988; 108:616–625. (Erratum, Annals of Internal Medicine 1988; 109:348.) Winner III, L, Mack J, Weltzin R, Mekalanos JJ, Kraehenhbuhl JP, Neutra MR. New model for analysis of mucosal immunity: intestinal secretion of specific monoclonal immunoglobulin A from hybridoma tumors protects against Vibrio cholerae infection. Infection and Immunity 1991; 59:977–982. Wolf JL, Bye WA. The membranous epithelial (M) cell and the mucosal immune system. Annual Review of Medicine 1984; 35:95–112. Wolf JL, Rubin DH, Finberg R, et al. Intestinal M cells: a pathway for entry of reovirus into the host. Science 1981; 212:471–472. Wolfson MC. Health-adjusted life expectancy. Health Reports 1996; 8:41–46. Wrenn K, Zeldin M, Miller O. Influenza and pneumococcal vaccination in the emergency department: Is it feasible? Journal of General Internal Medicine 1994; 9:425–429. Yang Y, Nunes FA, Berencs K, et al. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proceedings of the National Academy of Sciences 1994; 91:4407–4411. Yap KL, Ada GL, McKenzie IFC. Transfer on specific cytotoxic T lymphocytes protects mice inoculated with influenzae virus. Nature 1978; 273:238–239. Zinkernagel RM, Doherty PC. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Advances in Immunology 1979; 27:51–177. Zweerink HJ, Courtneidge SA, Skehel JJ, et al. Cytotoxic T cells kill influenzae virus-infected cells but do not distinguish between serologically distinct type A viruses. Nature 1977; 267:354–356.

OCR for page 133
Vaccines for the 21st Century: A Tool for Decisionmaking This page in the original is blank.